Consensus recommendations for the diagnosis and clinical
management of Rosai-Dorfman-Destombes disease

J 2018

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

ABLA, Oussama, Eric JACOBSEN, Jennifer PICARSIC, Zdenka KŘENOVÁ, Ronald JAFFE et. al.

Základní údaje

Originální název

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

Autoři

ABLA, Oussama (124 Kanada, garant), Eric JACOBSEN (840 Spojené státy), Jennifer PICARSIC (840 Spojené státy), Zdenka KŘENOVÁ (203 Česká republika, domácí), Ronald JAFFE (840 Spojené státy), Jean-Francois EMILE (250 Francie), Benjamin H. DURHAM (840 Spojené státy), Jorge BRAIER (32 Argentina), Frederic CHARLOTTE (250 Francie), Jean DONADIEU (250 Francie), Fleur COHEN-AUBART (250 Francie), Carlos RODRIGUEZ-GALINDO (840 Spojené státy), Carl ALLEN (840 Spojené státy), James A. WHITLOCK (124 Kanada), Sheila WEITZMAN (124 Kanada), Kenneth L. MCCLAIN (840 Spojené státy), Julien HAROCHE (250 Francie) a Eli L. DIAMOND (840 Spojené státy)

Vydání

Blood, Washington, American Society of Hematology, 2018, 0006-4971

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 16.601

Kód RIV

RIV/00216224:14110/18:00104163

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1182/blood-2018-03-839753

UT WoS

000439123700004

Klíčová slova anglicky

Rosai-Dorfman-Destombes disease

Štítky

14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2019 21:56, Soňa Böhmová

Anotace

V originále

Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to the R group of the 2016 revised histiocytosis classification, is a widely heterogeneous entity with a range of clinical phenotypes occurring in isolation or in association with autoimmune or malignant diseases. Recent studies have found NRAS, KRAS, MAP2K1, and ARAF mutations in lesional tissues, raising the possibility of a clonal origin in some forms of RDD. More than 1000 reports have been published in the English literature; however, there is a lack of consensus regarding approach for the clinical management of RDD. Although in most cases RDD can be observed or treated with local therapies, some patients with refractory or multifocal disease experience morbidity and mortality. Here we provide the first consensus multidisciplinary recommendations for the diagnosis and management of RDD. These recommendations were discussed at the 32nd Histiocyte Society Meeting by an international group of academic clinicians and pathologists with expertise in RDD. We include guidelines for clinical, laboratory, pathologic, and radiographic evaluation of patients with RDD together with treatment recommendations based on clinical experience and review of the literature.

Citovat

ABLA, Oussama, Eric JACOBSEN, Jennifer PICARSIC, Zdenka KŘENOVÁ, Ronald JAFFE, Jean-Francois EMILE, Benjamin H. DURHAM, Jorge BRAIER, Frederic CHARLOTTE, Jean DONADIEU, Fleur COHEN-AUBART, Carlos RODRIGUEZ-GALINDO, Carl ALLEN, James A. WHITLOCK, Sheila WEITZMAN, Kenneth L. MCCLAIN, Julien HAROCHE a Eli L. DIAMOND. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. Washington: American Society of Hematology, 2018, roč. 131, č. 26, s. 2877-2890. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2018-03-839753.

@article{1454376,
   author = {Abla, Oussama and Jacobsen, Eric and Picarsic, Jennifer and Křenová, Zdenka and Jaffe, Ronald and Emile, JeanandFrancois and Durham, Benjamin H. and Braier, Jorge and Charlotte, Frederic and Donadieu, Jean and CohenandAubart, Fleur and RodriguezandGalindo, Carlos and Allen, Carl and Whitlock, James A. and Weitzman, Sheila and McClain, Kenneth L. and Haroche, Julien and Diamond, Eli L.},
   article_location = {Washington},
   article_number = {26},
   doi = {http://dx.doi.org/10.1182/blood-2018-03-839753},
   keywords = {Rosai-Dorfman-Destombes disease},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease},
   volume = {131},
   year = {2018}
}

TY  - JOUR
ID  - 1454376
AU  - Abla, Oussama - Jacobsen, Eric - Picarsic, Jennifer - Křenová, Zdenka - Jaffe, Ronald - Emile, Jean-Francois - Durham, Benjamin H. - Braier, Jorge - Charlotte, Frederic - Donadieu, Jean - Cohen-Aubart, Fleur - Rodriguez-Galindo, Carlos - Allen, Carl - Whitlock, James A. - Weitzman, Sheila - McClain, Kenneth L. - Haroche, Julien - Diamond, Eli L.
PY  - 2018
TI  - Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
JF  - Blood
VL  - 131
IS  - 26
SP  - 2877-2890
EP  - 2877-2890
PB  - American Society of Hematology
SN  - 00064971
KW  - Rosai-Dorfman-Destombes disease
N2  - Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to the R group of the 2016 revised histiocytosis classification, is a widely heterogeneous entity with a range of clinical phenotypes occurring in isolation or in association with autoimmune or malignant diseases. Recent studies have found NRAS, KRAS, MAP2K1, and ARAF mutations in lesional tissues, raising the possibility of a clonal origin in some forms of RDD. More than 1000 reports have been published in the English literature; however, there is a lack of consensus regarding approach for the clinical management of RDD. Although in most cases RDD can be observed or treated with local therapies, some patients with refractory or multifocal disease experience morbidity and mortality. Here we provide the first consensus multidisciplinary recommendations for the diagnosis and management of RDD. These recommendations were discussed at the 32nd Histiocyte Society Meeting by an international group of academic clinicians and pathologists with expertise in RDD. We include guidelines for clinical, laboratory, pathologic, and radiographic evaluation of patients with RDD together with treatment recommendations based on clinical experience and review of the literature.
ER  -

ABLA, Oussama, Eric JACOBSEN, Jennifer PICARSIC, Zdenka KŘENOVÁ, Ronald JAFFE, Jean-Francois EMILE, Benjamin H. DURHAM, Jorge BRAIER, Frederic CHARLOTTE, Jean DONADIEU, Fleur COHEN-AUBART, Carlos RODRIGUEZ-GALINDO, Carl ALLEN, James A. WHITLOCK, Sheila WEITZMAN, Kenneth L. MCCLAIN, Julien HAROCHE a Eli L. DIAMOND. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. \textit{Blood}. Washington: American Society of Hematology, 2018, roč.~131, č.~26, s.~2877-2890. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2018-03-839753.

Podrobný výpis o publikaci